It’s the medical revolution of the decade: GLP-1 drugs, like Ozempic or Wegovy, are transforming the management of diabetes and obesity. But as scientific hindsight finally reaches five to ten years, new warning signals appear. A major study presented at the 2026 Annual Meeting of Orthopedic Surgeons (AAOS) reveals that these treatments could silently weaken our musculoskeletal system. Between the risk of osteoporosis and attacks of gout, the price of rapid weight loss could be heavier than expected for our joints.
The hidden side of rapid weight loss
Michigan State University researchers analyzed the medical records of more than 146,000 people to understand the long-term impact of GLP-1 receptor agonists. The finding is statistically speaking: users of semaglutide or liraglutide have a slightly higher risk of developing osteoporosis (+0.9%), gout (+0.8%) or osteomalacia (+0.1%), a rare metabolic disease which softens the bones.
How to explain this phenomenon? Several avenues are explored. Sudden and massive weight loss is known to stress the bone system. In addition, too rapid fat loss can cause a surge in uric acid levels in the blood, the direct trigger of gout attacks. Finally, these medications, by radically suppressing the appetite, could lead to nutritional deficiencies in calcium and vitamin D, vital elements for the repair of our skeleton.
An orthopedic paradox
However, the situation is not all gloomy. “ We are just reaching the point of no return where long-term monitoring data begins to become available“, explains Muaaz Wajahath, lead author of the study. Paradoxically, other research shows that patients on GLP-1 recover better after hip or knee replacement, likely due to reduced mechanical loading on their joints and better control of osteoarthritis-related inflammation.
This dual aspect of GLP-1 – protective for some, weakening for others – suggests that the risk/benefit ratio must be assessed on a case-by-case basis. Clinicians are now encouraged to monitor their patients’ bone density more closely, especially if they already have vulnerability factors.
Towards a personalized prescription
It is not a question of demonizing these treatments, but of refining their use. The relative novelty of these molecules means that our view of their systemic effects is still incomplete. In addition to bone risks, links have been mentioned with muscle loss or pancreatic problems.
« Any drug that sees such rapid adoption deserves serious scrutiny“, insists Wajahath. The future challenge will be to personalize prescriptions: if a patient is at risk of osteoporosis, increased monitoring or therapeutic alternatives could be preferable. In the meantime, a diet rich in essential nutrients and appropriate physical activity remain the best allies for protecting your skeleton during slimming treatment.
This research work was presented during the 2026 Annual Meeting of the American Academy of Orthopedic Surgeons (AAOS).
